摘要Objective: To systematically evaluate the clinical efficacy and safety of Hanchuan Zupa granule(HCZPG) in the treatment of bronchial asthma. Methods: The Cochrane Library, Pubmed, EMBASE, CNKI, CBM, VIP and Wanfang were searched up to June 2021. Randomized controlled trials, which assessed the effects of HCZPG in the treatment of bronchial asthma, were included in this review, and the references included in the selected studies were also tracked. The methodological quality of eligible studies were assessed by the Cochrane Collaboration's tool. Data of the included studies were extracted independently by two authors and meta-analysis was conducted using RevMan5.3. Results: A total of 97 relevant literatures were retrieved, and 13 studies were finally included, involving 1189 patients. The aggregated meta-analysis results indicated that HCZPG improved total clinical efficacy [RR=1.18,95％ CI (1.13,1.24),P<0.00001], FEV1(L)[WMD=0.48,95％ CI (0.22,0.74),P=0.0003], FVC(L)[WMD=1.23,95％ CI (0.5,1.96),P=0.001], FEV1/FVC(％) [WMD=7.37,95％ CI (5.91,8.84),P<0.00001], PEF [SMD=1.19,95％ CI (0.82,1.56),P<0.00001], IL-4 [WMD=-12.13,95％ CI (-16.36,-7.90), P<0.00001], IL-6 [WMD=-29.55,95％ CI (-40.71,-18.39),P<0.00001], TNF-α[SMD=-2.73,95％CI (-3.57,-1.88),P<0.00001],PaO2[WMD=8.97,95％ CI (6.09,11.85),P<0.00001], but the risk of adverse events were not statistically significant between the two groups [RR=0.68,95％CI (0.39,1.18),P=0.17]. Conclusion: HCZPG shows good clinical curative effects in treating bronchial asthma without increasing the incidence of adverse events.